161 related articles for article (PubMed ID: 8416022)
1. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder.
Goddard AW; Woods SW; Sholomskas DE; Goodman WK; Charney DS; Heninger GR
Psychiatry Res; 1993 Aug; 48(2):119-33. PubMed ID: 8416022
[TBL] [Abstract][Full Text] [Related]
2. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.
Charney DS; Woods SW; Krystal JH; Nagy LM; Heninger GR
Acta Psychiatr Scand; 1992 Oct; 86(4):273-82. PubMed ID: 1333719
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluvoxamine on panic disorder.
Hoehn-Saric R; McLeod DR; Hipsley PA
J Clin Psychopharmacol; 1993 Oct; 13(5):321-6. PubMed ID: 8227490
[TBL] [Abstract][Full Text] [Related]
4. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin.
Den Boer JA; Westenberg HG
Psychopharmacology (Berl); 1990; 102(1):85-94. PubMed ID: 1697419
[TBL] [Abstract][Full Text] [Related]
5. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
[TBL] [Abstract][Full Text] [Related]
6. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder.
Charney DS; Woods SW; Heninger GR
Psychiatry Res; 1989 Feb; 27(2):173-82. PubMed ID: 2540501
[TBL] [Abstract][Full Text] [Related]
7. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks.
Charney DS; Woods SW; Goodman WK; Heninger GR
Am J Psychiatry; 1987 Aug; 144(8):1030-6. PubMed ID: 3037926
[TBL] [Abstract][Full Text] [Related]
8. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures.
Albus M; Zahn TP; Breier A
Eur Arch Psychiatry Clin Neurosci; 1992; 241(6):337-44. PubMed ID: 1504110
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
Nair NP; Bakish D; Saxena B; Amin M; Schwartz G; West TE
Anxiety; 1996; 2(4):192-8. PubMed ID: 9160622
[TBL] [Abstract][Full Text] [Related]
10. Noradrenergic dysregulation during discontinuation of cocaine use in addicts.
McDougle CJ; Black JE; Malison RT; Zimmermann RC; Kosten TR; Heninger GR; Price LH
Arch Gen Psychiatry; 1994 Sep; 51(9):713-9. PubMed ID: 8080348
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.
Palatnik A; Frolov K; Fux M; Benjamin J
J Clin Psychopharmacol; 2001 Jun; 21(3):335-9. PubMed ID: 11386498
[TBL] [Abstract][Full Text] [Related]
12. MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients. A preliminary report.
Slaap BR; van Vliet IM; Westenberg HG; Den Boer JA
Psychopharmacology (Berl); 1996 Oct; 127(4):353-8. PubMed ID: 8923571
[TBL] [Abstract][Full Text] [Related]
13. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
[TBL] [Abstract][Full Text] [Related]
14. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
Fux M; Taub M; Zohar J
Acta Psychiatr Scand; 1993 Oct; 88(4):235-7. PubMed ID: 8256637
[TBL] [Abstract][Full Text] [Related]
15. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder.
Charney DS; Heninger GR; Breier A
Arch Gen Psychiatry; 1984 Aug; 41(8):751-63. PubMed ID: 6742977
[TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine attenuates panic induced by 35% CO2 challenge.
Pols HJ; Hauzer RC; Meijer JA; Verburg K; Griez EJ
J Clin Psychiatry; 1996 Nov; 57(11):539-42. PubMed ID: 8968304
[TBL] [Abstract][Full Text] [Related]
17. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls.
Gurguis GN; Uhde TW
Psychoneuroendocrinology; 1990; 15(3):217-24. PubMed ID: 2255749
[TBL] [Abstract][Full Text] [Related]
18. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects.
Goddard AW; Charney DS; Germine M; Woods SW; Heninger GR; Krystal JH; Goodman WK; Price LH
Biol Psychiatry; 1995 Jul; 38(2):74-85. PubMed ID: 7578653
[TBL] [Abstract][Full Text] [Related]
19. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults.
Vasa RA; Pine DS; Masten CL; Vythilingam M; Collin C; Charney DS; Neumeister A; Mogg K; Bradley BP; Bruck M; Monk CS
Psychopharmacology (Berl); 2009 Jun; 204(3):445-55. PubMed ID: 19266185
[TBL] [Abstract][Full Text] [Related]
20. Yohimbine premedication and 35% CO2 vulnerability in healthy volunteers.
Pols H; Griez E; Verburg K; van der Werf D
Eur Arch Psychiatry Clin Neurosci; 1994; 244(2):81-5. PubMed ID: 7948058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
